Company Overview

Pfizer reports third-quarter 2026 results this morning before the market opens, in the same session as the U.S. midterm elections. After the vaccine-driven boom of 2021 and 2022, Pfizer has spent the past few years resetting around a different set of products: cancer drugs from its Seagen acquisition, newer launches, and an obesity pipeline built through its purchase of Metsera, a deal valued near $10 billion that closed in late 2025. This quarter is the first checkpoint on whether that reset is holding up.

When Pfizer last reported, on August 4, it beat expectations. Adjusted EPS was $0.77 against a consensus of about $0.68, and revenue of $15.03 billion beat the roughly $14.40 billion estimate. Revenue from launched and acquired products grew 18% on an operational basis. Management raised the low end of its 2026 revenue guidance to $60.5 billion to $62.5 billion while reaffirming adjusted EPS guidance of $2.80 to $3.00, even after absorbing roughly $0.10 of impact from the Innovent transaction. The stock closed up about 1.5% that day.

The setup for this morning is different from a typical earnings report. Options markets were pricing a move of roughly 5.1% either way as of late October, above the stock’s 10-year average post-earnings move of about 3.6%. Pfizer closed at $29.58 on October 16, the latest price I could confirm, which puts the dividend yield near 5.8%. Readers should check this morning’s tape for the confirmed numbers and the current price.

Key Technical and Fundamental Drivers

Earnings This Morning → A Raised Revenue Outlook Gets Its First Test
Pfizer’s Q2 print came with a $500 million increase to the midpoint of its full-year revenue guidance. Management said its non-COVID products were running about $1.5 billion ahead of its earlier expectations. At the same time, it cut its 2026 COVID-19 revenue estimate to about $4 billion from $5 billion, mainly on weaker Paxlovid demand. Q3 is the first quarter that shows whether the non-COVID strength continued and whether the COVID reduction is the end of that adjustment or the start of a bigger one. Analysts were looking for adjusted EPS of about $0.75.

Obesity Pipeline → Ten Pivotal Trials Planned for 2026
Pfizer plans to start about 20 pivotal trials in 2026, including ten for the ultra-long-acting obesity assets acquired from Metsera. Its monthly GLP-1 candidate, berobenatide, showed Phase IIb efficacy that the company says is comparable to tirzepatide, with monthly dosing as the convenience advantage. That is early-stage data, not an approval, and the obesity market is dominated by Eli Lilly and Novo Nordisk. But it gives the company a credible entry into a category where it had been absent, and any update on timelines will be watched closely.

Oncology → A Second Growth Leg Beyond Seagen
Alongside obesity, Pfizer is running four pivotal trials for PF-08634404, a PD-1 x VEGF bispecific antibody in-licensed from 3SBio, and highlighted continued progress on Padcev and mevrometostat. Oncology is where the Seagen acquisition was meant to pay off, and the 18% operational growth in launched and acquired products in Q2 suggests the portfolio is gaining traction even as older products face competition.

Costs and Cash → A $9.7 Billion Savings Target and Steady Cash Generation
Pfizer expanded its cost-savings target to about $9.7 billion through 2029. In Q2 it generated $3.45 billion in operating cash flow and ended the quarter with leverage of 2.7 times. No share repurchases were completed in the first half and current guidance assumes none in 2026, which means cash is going toward debt reduction, the pipeline, and the dividend rather than buybacks.

The Dividend → About 5.8% at $29.58, With Management Committed Through the Patent Cliff
Pfizer pays $0.43 per quarter, or $1.72 annualized, a yield of roughly 5.8% at the October 16 close. CEO Albert Bourla said the company expects to maintain the dividend through its upcoming loss-of-exclusivity period and eventually resume dividend growth. That commitment is the main reason many income investors own the stock, and it is also the part of the story that deserves the most scrutiny, as noted below.

Market Takeaway

Pfizer is a “show me” stock: a large, cash-generating drugmaker with a high yield, an expanding pipeline, and a company-wide cost program, trading as though investors want proof that the next growth chapter arrives before the current products lose exclusivity. This morning’s report is another data point on that question. A quarter that confirms the raised revenue outlook and keeps adjusted EPS inside its $2.80 to $3.00 range would support the argument that the reset is on track.

The risks are real and specific. Pfizer faces a wave of patent expirations on major products, and its guidance explicitly reflects the anticipated unfavorable impact of Most-Favored-Nation drug pricing and TrumpRx, so policy headlines can move the stock regardless of earnings. The dividend payout exceeds 100% of reported earnings on a GAAP basis, and Q2 produced a reported loss per share of $0.04 because of a large non-cash impairment charge, so coverage depends on adjusted earnings holding up. Paxlovid demand is weakening, and the obesity pipeline is promising but unproven in a market where larger competitors are already established. And with options pricing a larger-than-usual move, a modest miss on guidance could produce a sharp reaction in either direction. For readers watching Tuesday’s session, with midterm elections underway and a heavy slate of earnings, Pfizer offers a income-oriented way to follow healthcare’s biggest question: whether a company with falling legacy revenue can build enough new products to cover the gap.